300
Participants
Start Date
November 30, 2015
Primary Completion Date
April 30, 2017
Study Completion Date
April 30, 2017
Interrupted apixaban
Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
Uninterrupted apixaban
Intervention description: Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
Site 0009, Philadelphia
Site 0003, Richmond
Site 0010, Charleston
Site 0016, Pensacola
Site 0020, Huntsville
Site 0002, Toledo
Site 0014, West Des Moines
Site 0006, Kansas City
Site 0021, Omaha
Site 0007, Oklahoma City
Site 0017, Austin
Site 0019, Albuquerque
Site 0005, Mission Viejo
Site 0012, New Haven
Site 0011, Trumbull
Site 0018, Bangor
Site 0004, Scarborough
Site 0008, Boston
Site 0001, Burlington
Lead Sponsor
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Baim Institute for Clinical Research
OTHER